What is the future for PD pathway inhibitors in combination with platinum-based doublets as frontline therapy for advanced NSCLC?

What is the future for PD pathway inhibitors in combination with platinum-based doublets as frontline therapy for advanced NSCLC?

lung

4 years
388 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
Report 0 0
Category:
Description:
DAVID ROSS CAMIDGE, MD, PHD, of the University of Colorado Denver answers the question what is the future for PD pathway inhibitors in combination with platinum-based doublets as frontline therapy for advanced NSCLC?
Up Next Autoplay